---
document_datetime: 2025-12-29 11:45:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/peyona.html
document_name: peyona.html
version: success
processing_time: 0.1433891
conversion_datetime: 2025-12-30 02:38:34.642801
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Peyona (previously Nymusa)

[RSS](/en/individual-human-medicine.xml/66663)

##### Authorised

This medicine is authorised for use in the European Union

caffeine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Peyona](#more-information-on-peyona-750)
- [Preventing medication errors](#preventing-medication-errors-1390)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Peyona is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than 20 seconds.

Peyona contains the active substance caffeine citrate.

Expand section

Collapse section

## How is Peyona used?

Peyona can only be obtained with a prescription. A doctor with experience of treating newborn babies on intensive care should supervise the start of treatment with the medicine. Peyona should be given only in an intensive care unit for newborns that is well equipped to closely monitor the baby.

The dose of Peyona is calculated using the baby's weight. The first dose (of 20 mg caffeine citrate per kilogram of bodyweight) is given by infusion (drip) into a vein over 30 minutes, using a device to closely control the rate at which the medicine is given. To continue treatment, Peyona is given in lower doses (5 mg caffeine citrate per kilogram of bodyweight) every 24 hours. These lower doses can be given either by infusion over 10 minutes or by mouth (e.g. through a tube into the stomach). Treatment usually continues until the baby can breathe well enough for at least 5 days.

For more information about using Peyona, see the package leaflet or contact your doctor or pharmacist.

## How does Peyona work?

Apnoea in premature babies occurs because the part of the baby's brain that controls breathing ('breathing centre') is not fully developed.

Caffeine citrate, the active substance in Peyona, blocks the effect of adenosine. Adenosine is a natural substance that slows down the activity of some parts of the brain including the breathing centre. By reducing the effect of adenosine, caffeine citrate stimulates the brain to resume breathing.

## What benefits of Peyona have been shown in studies?

Because caffeine citrate has been used in premature babies for a long time, the company presented information from published scientific literature.

In a study involving 85 premature babies who had had several episodes of apnoea, caffeine citrate was compared with placebo (a dummy treatment) over 10 days. On 6 out of 10 days, caffeine citrate was more effective than placebo in reducing the number of apnoea episodes by at least a half. In addition, 22% of babies given caffeine citrate had at least 8 days with no apnoea compared with none of babies who received placebo.

A study involving 2,006 premature babies with apnoea found that 46% of babies given placebo died or had neurological disabilities compared with 40% of babies given caffeine citrate.

A review of five studies compared caffeine or theophylline (another stimulant) with placebo in 192 premature babies with apnoea. The review considered a baby to be in treatment failure if there was no halving of the number of apnoea episodes, if the baby required a machine to help with breathing or if the baby died. Fewer babies treated with caffeine or theophylline had treatment failure compared with placebo.

## What are the risks associated with Peyona?

The most common side effects with Peyona (which may affect up to 1 in 10 babies) are hyperglycaemia (high blood glucose levels), tachycardia (rapid heartbeat), and phlebitis (inflammation of a vein) and inflammation at the site of infusion.

For the full list of side effects and restrictions of Peyona, see the package leaflet.

## Why is Peyona authorised in the EU?

The European Medicines Agency decided that Peyona's benefits are greater than its risks and it can be authorised for use in the EU. Published scientific literature has shown that Peyona is effective and its side effects are manageable.

## What measures are being taken to ensure the safe and effective use of Peyona?

The company that markets Peyona will provide a card to display in intensive care units where the medicine will be used. It will include information, warnings and precautions on the appropriate and safe use of Peyona, including how to work out and prescribe the dose.

Recommendations and precautions for the safe and effective use of Peyona have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Peyona are continuously monitored. Side effects reported with Peyona are carefully evaluated and any necessary action taken to protect patients.

## Other information about Peyona

Nymusa received a marketing authorisation valid throughout the EU on 2 July 2009. The name of the medicine was changed to Peyona on 24 November 2010.

Peyona : EPAR - Medicine overview

Reference Number: EMA/480124/2020

English (EN) (134.23 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 16/09/2020

[View](/en/documents/overview/peyona-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-872)

български (BG) (172.34 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/bg/documents/overview/peyona-epar-medicine-overview_bg.pdf)

español (ES) (123.07 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/es/documents/overview/peyona-epar-medicine-overview_es.pdf)

čeština (CS) (170.48 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/cs/documents/overview/peyona-epar-medicine-overview_cs.pdf)

dansk (DA) (146.93 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/da/documents/overview/peyona-epar-medicine-overview_da.pdf)

Deutsch (DE) (150.18 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/de/documents/overview/peyona-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.78 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/et/documents/overview/peyona-epar-medicine-overview_et.pdf)

ελληνικά (EL) (170.06 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/el/documents/overview/peyona-epar-medicine-overview_el.pdf)

français (FR) (148.15 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/fr/documents/overview/peyona-epar-medicine-overview_fr.pdf)

hrvatski (HR) (168.71 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/hr/documents/overview/peyona-epar-medicine-overview_hr.pdf)

italiano (IT) (146.21 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/it/documents/overview/peyona-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (160.5 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/lv/documents/overview/peyona-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (169.85 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/lt/documents/overview/peyona-epar-medicine-overview_lt.pdf)

magyar (HU) (167.01 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/hu/documents/overview/peyona-epar-medicine-overview_hu.pdf)

Malti (MT) (179.82 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/mt/documents/overview/peyona-epar-medicine-overview_mt.pdf)

Nederlands (NL) (146.76 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/nl/documents/overview/peyona-epar-medicine-overview_nl.pdf)

polski (PL) (171.21 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/pl/documents/overview/peyona-epar-medicine-overview_pl.pdf)

português (PT) (124.21 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/pt/documents/overview/peyona-epar-medicine-overview_pt.pdf)

română (RO) (142.72 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/ro/documents/overview/peyona-epar-medicine-overview_ro.pdf)

slovenčina (SK) (170.53 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/sk/documents/overview/peyona-epar-medicine-overview_sk.pdf)

slovenščina (SL) (166.66 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/sl/documents/overview/peyona-epar-medicine-overview_sl.pdf)

Suomi (FI) (144.99 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/fi/documents/overview/peyona-epar-medicine-overview_fi.pdf)

svenska (SV) (145.97 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

16/09/2020

[View](/sv/documents/overview/peyona-epar-medicine-overview_sv.pdf)

Peyona : EPAR - Risk-management-plan summary

English (EN) (206.99 KB - PDF)

**First published:** 14/09/2021

[View](/en/documents/rmp-summary/peyona-epar-risk-management-plan-summary_en.pdf)

## Product information

Peyona : EPAR - Product Information

English (EN) (215.35 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 18/09/2024

[View](/en/documents/product-information/peyona-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-811)

български (BG) (254.43 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/bg/documents/product-information/peyona-epar-product-information_bg.pdf)

español (ES) (213.46 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/es/documents/product-information/peyona-epar-product-information_es.pdf)

čeština (CS) (224.84 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/cs/documents/product-information/peyona-epar-product-information_cs.pdf)

dansk (DA) (204.54 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/da/documents/product-information/peyona-epar-product-information_da.pdf)

Deutsch (DE) (224.1 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/de/documents/product-information/peyona-epar-product-information_de.pdf)

eesti keel (ET) (208.08 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/et/documents/product-information/peyona-epar-product-information_et.pdf)

ελληνικά (EL) (254.65 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/el/documents/product-information/peyona-epar-product-information_el.pdf)

français (FR) (218.92 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/fr/documents/product-information/peyona-epar-product-information_fr.pdf)

hrvatski (HR) (217.5 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/hr/documents/product-information/peyona-epar-product-information_hr.pdf)

íslenska (IS) (214.06 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/is/documents/product-information/peyona-epar-product-information_is.pdf)

italiano (IT) (215.6 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/it/documents/product-information/peyona-epar-product-information_it.pdf)

latviešu valoda (LV) (232.51 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/lv/documents/product-information/peyona-epar-product-information_lv.pdf)

lietuvių kalba (LT) (226 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/lt/documents/product-information/peyona-epar-product-information_lt.pdf)

magyar (HU) (219.92 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/hu/documents/product-information/peyona-epar-product-information_hu.pdf)

Malti (MT) (235.11 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/mt/documents/product-information/peyona-epar-product-information_mt.pdf)

Nederlands (NL) (213.18 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/nl/documents/product-information/peyona-epar-product-information_nl.pdf)

norsk (NO) (200.35 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/no/documents/product-information/peyona-epar-product-information_no.pdf)

polski (PL) (207.14 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/pl/documents/product-information/peyona-epar-product-information_pl.pdf)

português (PT) (214.82 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/pt/documents/product-information/peyona-epar-product-information_pt.pdf)

română (RO) (227.46 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/ro/documents/product-information/peyona-epar-product-information_ro.pdf)

slovenčina (SK) (224.01 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/sk/documents/product-information/peyona-epar-product-information_sk.pdf)

slovenščina (SL) (213.75 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/sl/documents/product-information/peyona-epar-product-information_sl.pdf)

Suomi (FI) (198.2 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/fi/documents/product-information/peyona-epar-product-information_fi.pdf)

svenska (SV) (208.09 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

18/09/2024

[View](/sv/documents/product-information/peyona-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0032 27/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Peyona : EPAR - All Authorised presentations

English (EN) (66.87 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 15/12/2010

[View](/en/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-258)

български (BG) (74.52 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/bg/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_bg.pdf)

español (ES) (65.83 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/es/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_es.pdf)

čeština (CS) (82.91 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/cs/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (65.3 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/da/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (69.05 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/de/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.26 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/et/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.07 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/el/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_el.pdf)

français (FR) (66.07 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/fr/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (22.73 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/hr/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (68.98 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/is/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_is.pdf)

italiano (IT) (65.11 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/it/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (100.21 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/lv/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (99.56 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/lt/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (96.79 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/hu/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (96.01 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/mt/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (67.01 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/nl/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (67.64 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/no/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_no.pdf)

polski (PL) (100.58 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/pl/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_pl.pdf)

português (PT) (65.81 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/pt/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_pt.pdf)

română (RO) (93.81 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/ro/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (81.68 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/sk/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.25 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/sl/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (64.12 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/fi/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (67.19 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

15/12/2010

[View](/sv/documents/all-authorised-presentations/peyona-epar-all-authorised-presentations_sv.pdf)

Peyona : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (18.55 KB - PDF)

**First published:** 03/07/2009

**Last updated:** 15/12/2010

[View](/en/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (23)](#file-language-dropdown-924)

български (BG) (112.35 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/bg/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (18.53 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/es/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (107.44 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/cs/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (20.88 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/da/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (21.72 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/de/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (17.06 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/et/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (192.84 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/el/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (17.26 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/fr/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

íslenska (IS) (17 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/is/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_is.pdf)

italiano (IT) (17.28 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/it/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (181.92 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/lv/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (177.91 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/lt/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (101.81 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/hu/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (179.32 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/mt/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (17.42 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/nl/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

norsk (NO) (17.62 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/no/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_no.pdf)

polski (PL) (180.93 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/pl/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (19.11 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/pt/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (178.3 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/ro/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (177.03 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/sk/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (172.42 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/sl/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (15.85 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/fi/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (18.39 KB - PDF)

**First published:**

03/07/2009

**Last updated:**

15/12/2010

[View](/sv/documents/conditions-member-states/peyona-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Peyona (previously Nymusa) Active substance Caffeine citrate International non-proprietary name (INN) or common name caffeine Therapeutic area (MeSH) Apnea Anatomical therapeutic chemical (ATC) code N06BC01

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Treatment of primary apnoea of premature newborns.

## Authorisation details

EMA product number EMEA/H/C/001014 Marketing authorisation holder

Chiesi Farmaceutici SpA

Via Palermo 26/A

Opinion adopted 23/04/2009 Marketing authorisation issued 02/07/2009 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Peyona : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (132.33 KB - PDF)

**First published:** 15/06/2010

**Last updated:** 18/09/2024

[View](/en/documents/procedural-steps-after/peyona-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Nymusa : EPAR - Public assessment report

English (EN) (829.32 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 06/07/2009

[View](/en/documents/assessment-report/nymusa-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Nymusa

Reference Number: EMEA/CHMP/212696/2009

English (EN) (31.96 KB - PDF)

**First published:** 23/04/2009

**Last updated:** 23/04/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-nymusa_en.pdf)

#### More information on Peyona

This product is no longer an orphan medicine ( [EU/3/03/132](/en/medicines/human/orphan-designations/eu-3-03-132) ). It was originally designated an orphan medicine on 18 February 2003. Peyona was withdrawn from the Community register of orphan medicinal products in July 2019 at the end of the 10-year period of market exclusivity.

#### Preventing medication errors

Peyona: potential for dosing errors

Reference Number: EMA/480123/2020

Summary:

Peyona, a medicine for treating apnoea of prematurity, is a solution that contains the active substance caffeine citrate 20 mg/ml.

English (EN) (121.14 KB - PDF)

**First published:** 16/09/2020

[View](/en/documents/medication-error/peyona-potential-dosing-errors_en.pdf)

[Other languages (22)](#file-language-dropdown-184)

български (BG) (156.65 KB - PDF)

**First published:**

16/09/2020

[View](/bg/documents/medication-error/peyona-potential-dosing-errors_bg.pdf)

español (ES) (134.05 KB - PDF)

**First published:**

16/09/2020

[View](/es/documents/medication-error/peyona-potential-dosing-errors_es.pdf)

čeština (CS) (154.93 KB - PDF)

**First published:**

16/09/2020

[View](/cs/documents/medication-error/peyona-potential-dosing-errors_cs.pdf)

dansk (DA) (134.49 KB - PDF)

**First published:**

16/09/2020

[View](/da/documents/medication-error/peyona-potential-dosing-errors_da.pdf)

Deutsch (DE) (136.47 KB - PDF)

**First published:**

16/09/2020

[View](/de/documents/medication-error/peyona-potential-dosing-errors_de.pdf)

eesti keel (ET) (132.69 KB - PDF)

**First published:**

16/09/2020

[View](/et/documents/medication-error/peyona-potential-dosing-errors_et.pdf)

ελληνικά (EL) (153.75 KB - PDF)

**First published:**

16/09/2020

[View](/el/documents/medication-error/peyona-potential-dosing-errors_el.pdf)

français (FR) (133.12 KB - PDF)

**First published:**

16/09/2020

[View](/fr/documents/medication-error/peyona-potential-dosing-errors_fr.pdf)

hrvatski (HR) (149.45 KB - PDF)

**First published:**

16/09/2020

[View](/hr/documents/medication-error/peyona-potential-dosing-errors_hr.pdf)

italiano (IT) (133.15 KB - PDF)

**First published:**

16/09/2020

[View](/it/documents/medication-error/peyona-potential-dosing-errors_it.pdf)

latviešu valoda (LV) (169.31 KB - PDF)

**First published:**

16/09/2020

[View](/lv/documents/medication-error/peyona-potential-dosing-errors_lv.pdf)

lietuvių kalba (LT) (153.82 KB - PDF)

**First published:**

16/09/2020

[View](/lt/documents/medication-error/peyona-potential-dosing-errors_lt.pdf)

magyar (HU) (150.29 KB - PDF)

**First published:**

16/09/2020

[View](/hu/documents/medication-error/peyona-potential-dosing-errors_hu.pdf)

Malti (MT) (154.54 KB - PDF)

**First published:**

16/09/2020

[View](/mt/documents/medication-error/peyona-potential-dosing-errors_mt.pdf)

Nederlands (NL) (133.21 KB - PDF)

**First published:**

16/09/2020

[View](/nl/documents/medication-error/peyona-potential-dosing-errors_nl.pdf)

polski (PL) (152.88 KB - PDF)

**First published:**

16/09/2020

[View](/pl/documents/medication-error/peyona-potential-dosing-errors_pl.pdf)

português (PT) (134.55 KB - PDF)

**First published:**

16/09/2020

[View](/pt/documents/medication-error/peyona-potential-dosing-errors_pt.pdf)

română (RO) (153.02 KB - PDF)

**First published:**

16/09/2020

[View](/ro/documents/medication-error/peyona-potential-dosing-errors_ro.pdf)

slovenčina (SK) (154.15 KB - PDF)

**First published:**

16/09/2020

[View](/sk/documents/medication-error/peyona-potential-dosing-errors_sk.pdf)

slovenščina (SL) (150.76 KB - PDF)

**First published:**

16/09/2020

[View](/sl/documents/medication-error/peyona-potential-dosing-errors_sl.pdf)

Suomi (FI) (132.51 KB - PDF)

**First published:**

16/09/2020

[View](/fi/documents/medication-error/peyona-potential-dosing-errors_fi.pdf)

svenska (SV) (133.83 KB - PDF)

**First published:**

16/09/2020

[View](/sv/documents/medication-error/peyona-potential-dosing-errors_sv.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/09/2024

## Share this page

[Back to top](#main-content)